Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vercirnon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 known ✓ | P51686 | 17/20 | 1.00 |
| ▸ | CCR2 | P41597 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vercirnon SCHEMBL15766988 | 0.99 | CCR9 (0.98) | CCR9CCR2LMNAHTTTP53 | |
| Vercirnon SCHEMBL15766572 | 0.95 | CCR9 (0.90) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL15802910 | 0.92 | CCR9 (0.84) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL15761702 | 0.92 | CCR9 (0.84) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL344260 | 0.90 | CCR9 (1.00) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL14669216 | 0.90 | CCR9 (0.81) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL345005 | 0.89 | CCR9 (0.80) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL2167857 | 0.89 | CCR9 (0.80) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL2616498 | 0.88 | CCR9 (0.79) | CCR9CCR2HSD17B2 | |
| SCHEMBL27490 | 0.88 | CCR9 (0.78) | CCR9CCR2LMNAHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3993809-B1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | EISAI R&D MAN CO LTD (JP) | 2024-10-09 | — | — | EP | claimed |
| US-11911409-B2 | Pharmaceutical composition for treatment and prevention of chronic disease | STELIC INSTITUTE & CO., INC. (JP) | 2024-02-27 | — | — | US | claimed |
| EP-3552632-B1 | MEDICINAL COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY BOWEL DISEASE | STELIC INST & CO INC (JP) | 2023-07-12 | — | — | EP | claimed |
| EP-3554541-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BIORA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | claimed |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | claimed |
| US-20220323481-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CHRONIC DISEASE | STELIC INSTITUTE & CO., INC. (JP) | 2022-10-13 | — | — | US | claimed |
| US-20220304982-A1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-29 | — | — | US | claimed |
| EP-3993809-A1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | claimed |
| US-9150513-B2 | Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide | CHEMOCENTRYX, INC. (US) | 2015-10-06 | — | — | US | claimed |
| US-9139526-B2 | Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-9133124-B2 | Crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2015-09-15 | — | — | US | claimed |
| US-8815887-B2 | Prophylactic or therapeutic method for Sjogren's syndrome | MILLENIUM PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-20140171473-A1 | POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT- BUTYL -N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDE | CHEMOCENTRYX, INC. (US) | 2014-06-19 | — | — | US | claimed |
| WO-2014088113-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME USING SPECIFIC CCR9 RECEPTOR INHIBITORS/ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | claimed |
| EP-2740458-A1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP Gesellschaft für Management mbH (DE) | 2014-06-11 | — | — | EP | claimed |
| US-20140155437-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | claimed |
| US-20140155438-A1 | POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULFONAMIDE | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-20130059893-A1 | CRYSTALLINE FORM OF THE SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULFONAMIDE | CHEMOCENTRYX, INC. (US) | 2013-03-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | CCR9 261/4885CCR2 113/4885LMNA 2103/4885 |
| US-20140155437-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME | SSB, SCLY, HLA-DRB1 | CCR9 1218/4885CCR2 1700/4885LMNA 3957/4885 |
| US-20140171473-A1 | POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT- BUTYL -N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENE SULFONAMIDE | XRCC5, XRCC6, POT1 | CCR9 3571/4885CCR2 1630/4885LMNA 2933/4885 |
| US-11485737-B2 | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | CCR9 203/4885CCR2 334/4885LMNA 3645/4885 |
| US-20220304982-A1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | UGT1A6, ABCC1, CUL1 | CCR9 3179/4885CCR2 4526/4885LMNA 4417/4885 |
| US-20130059893-A1 | CRYSTALLINE FORM OF THE SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULFONAMIDE | TTR, REN, TBCA | CCR9 2292/4885CCR2 2772/4885LMNA 2994/4885 |
| US-20140155438-A1 | POLYMORPHIC FORMS OF THE SODIUM SALT OF 4-TERT-BUTYL-N-[4-CHLORO-2-(1-OXY-PYRIDINE-4-CARBONYL)-PHENYL]-BENZENESULFONAMIDE | KCNK4, SLC26A3, KCNK13 | CCR9 2134/4885CCR2 1318/4885LMNA 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.